Antifungal susceptibility profile of human-pathogenic species of Lichtheimia
- PMID: 20421405
- PMCID: PMC2897292
- DOI: 10.1128/AAC.01270-09
Antifungal susceptibility profile of human-pathogenic species of Lichtheimia
Abstract
Forty-four isolates belonging to human pathogenic species of Lichtheimia were tested against nine antifungal agents by using the EUCAST methodology. No remarkable differences were found between the clinical species, although L. ramosa showed slightly higher MICs for all drugs. Amphotericin B was the most active drug. Among azole drugs, posaconazole had the best activity in vitro and voriconazole was inactive. Echinocandins showed activity for some isolates, suggesting a potential role in combination therapy.
References
- 
    - Aberkane, A., M. Cuenca-Estrella, A. Gomez-Lopez, E. Petrikkou, E. Mellado, A. Monzon, and J. L. Rodriguez-Tudela. 2002. Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi. J. Antimicrob. Chemother. 50:719-722. - PubMed
 
- 
    - Alastruey-Izquierdo, A., M. V. Castelli, I. Cuesta, A. Monzon, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2009. Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. Antimicrob. Agents Chemother. 53:1686-1689. - PMC - PubMed
 
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
- Molecular Biology Databases
 
        